Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients.

Kerstin ClasenStefan WelzHeidrun FaltinDaniel ZipsFranziska Eckert

Published in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2021)

HMGB1 might be a promising marker to monitor ICD in HNSCC during the course of radiochemotherapy. However, HMGB1 seems to reflect complex and diverse immunogenic responses and potential confounders. Infections and treatment-associated toxicity should be considered when interpreting the dynamics of HMGB1.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
locally advanced
oxidative stress
prognostic factors
squamous cell carcinoma
radiation therapy
rectal cancer
combination therapy
patient reported